




Annual Report 2023

FRIDAY



ACXYYQEH

A11

01/03/2024

#158

COMPANIES HOUSE

Trustees' Report

For the year ended 30 June 2023

What we do and why it matters

The British Society for Immunology is the UK membership organisation working with scientists and clinicians to forward immunology research and application around the world. Our ambitious and collaborative community consists of over 4,300 immunologists, giving us a powerful voice to advocate on immunological science and health for the benefit of society.

The Society supports its members, students and the wider public to learn more about immunology through disseminating research and providing resources, activities and grants to aid education in this field.

Immunological science underpins many aspects of human and animal health and disease, from communicable disease and vaccination to the management and treatment of many chronic conditions. Through enhancing our knowledge of how the immune system functions for the public benefit, the British Society for Immunology can play a key role in advancing Society's ability to prevent and treat disease.

Our mission

The British Society for Immunology's mission is to support our immunology community in driving scientific discovery and making a positive impact on health.

We accomplish this by:


- **Connected community:** providing the immunology community with support to establish more connections and enhance collaboration, both within the field, and with other related scientific disciplines and between sectors.
- **Championing careers:** providing sector leading support to attract and retain talent in immunology.
- **Catalysing change:** influencing and improving the external environment to enable immunology to thrive and deliver positive outcomes for health.

The Trustees confirm they have referred to the Charity Commission's guidance on public benefit when reviewing the Society's aims and objectives, planning future activities and setting the annual operating plan.

Our strategic objectives

The British Society for Immunology strategy sets our direction and priorities for 2021-2025.

Building on the strong foundations of our past work and guided by our updated vision and mission statements and set of values, this ambitious strategy lays out how we will work with our membership to deliver for the immunology and wider community over the coming years. As the UK's leading charity and scientific society representing the immune research sector, we are confident that we will fulfil this strategy to lead a positive change towards our vision of better health for all through immunology.




Connected community

Our BSI community is at the heart of all we do. Being a member of the BSI means being a member of one of the largest immunology networks in the world. Immunology is a growing field, and the BSI aims to continually develop our activities and the support we provide to members to enable the discipline to flourish. Immunology intersects with numerous research fields, across different sectors, with the involvement of all career grades. Our goal is to bring this ecosystem together into a cohesive whole that fulfils our mission to take immunology forwards faster and more collaboratively.

Membership of the British Society for Immunology brings many benefits. These include discounts to our meetings and to our exceptional BSI Congress, access to a diverse range of grants, bursaries and prizes, free access to our journals and much more. The Society provides tailored support for our community through our highly valued Regional and Affinity Groups, but we are also there to represent immunology to the wider world. Members value our strong voice to speak out with influence and impact on behalf of immunology in policy, public engagement and the media.

At the end of June 2023, we had over 4,300 members who join us from all walks of immunology. From students up to senior levels, they contribute to our work through many different routes, including speaking at our conferences, helping with our public engagement activities and advising on our policy work – our grateful thanks go to our whole immunology community.

In December 2022, over 1,700 immunologists came together in Liverpool and online for our flagship event, BSI Congress 2022. It was an amazing four days of immunology, packed with cutting-edge science, inspiring debates and those all-important opportunities to connect and start new collaborations.



We look forward to welcoming the immunology community to Belfast in December for the 2023 BSI Congress.

Regional and Affinity Groups

The BSI's Regional and Affinity Groups are a key part of the BSI community and are part of our core activity to bring our membership together. The scientific discussions and networking that take place via these Groups are invaluable for the continued development of immunology. Our 17 Regional Groups bring together immunologists within a local community, boosting local research networks. Our 14 Affinity Groups have all been created to focus meetings and discussions on specific areas of immunology and they continue to evolve as immunology expands its reach and knowledge.

Our Groups ran a full programme of activities this year with a huge amount of enthusiasm, dedication and expertise. In total, our Groups hosted 12 in-person conferences and two online events, covering a whole host of topics from the ageing immune system to comparative immunology to inflammation at barrier sites. Collectively, these events attracted over 1,500 delegates and played an important part in our strategy to develop our Regional and Affinity Groups as community-based expert hubs. Our Groups also ran several other activities including in-house seminar series, careers events and public outreach initiatives.

BSI Journals

The BSI's original ethos still lies at the heart of our Society – to disseminate research with the aim of promoting and advancing immunology to foster future innovation. This has been a year of consolidation and growth for our highly respected family of three journals, *Clinical & Experimental Immunology*, *Immunotherapy Advances* and *Discovery Immunology*.

Working with our publishing partner, Oxford University Press, our journals aim to serve the field of immunology through publishing high-quality research articles, reviews, commentaries and short reports from researchers around the globe. We work closely with our Editors-in-Chief and Editorial Boards to take a strategic approach to ensure the continued high-performance of the journals. With our mixed portfolio of both hybrid and fully Open Access journals, the Society is in a strong position to continue to provide for the immunology community's publishing needs for many years to come.

Income generated from our journals provides major financial support for the Society's activities and we are hugely grateful to all our Editorial Board members for their ongoing commitment, and everyone who has contributed to the continued success of our journals, including authors, readers, reviewers and editors.



**Clinical & Experimental
IMMUNOLOGY**

Our established high quality and translational research journal, *Clinical & Experimental Immunology* (CEI), continues to go from strength to strength, with a robust impact factor of 4.6. This has been a busy year for the journal, led by Editor-in-Chief Leonie Taams, with several high-profile review series to take a deep dive into key topics including human B cells, inborn errors of immunity and therapeutic options for regulatory T cell enhancing approaches. Additionally, CEI's collaboration with the Federation of Clinical Immunology Societies (FOCIS) continues to strengthen with the publication of our series on unconventional T cells in health and disease.

Impact factor
4.6
(2022: 5.732)

Submissions
546
(2022: 537)

9.57
Avg citations
per article
(2022: 10.95)

*Citations are based on articles for previous two years.



Our first fully Open Access journal, *Immunotherapy Advances*, continues its progress to be a globally recognised title that both serves the immunotherapy community and exposes new developments in the field to a wide and diverse readership. Led by Editor-in-Chief, Tim Elliott, Immunotherapy Advances focuses on scientifically rigorous research relating to manipulations of the immune system for the benefit of human and animal health in all disease areas.

This year, the journal has passed the milestones of being accepted for inclusion in both PubMed Central and Scopus, which is a positive step forward as it means that the journal's content is more discoverable and searchable. The journal has also kept its foot on the pedal, publishing several special collections covering topics including immune-related adverse events, adoptive cellular therapies and T cell targeted approaches.



It's been a busy year for *Discovery Immunology* as we officially launched the content in October 2022 with six research and review articles. This new fully Open Access journal, led by Editor-in-Chief Simon Milling, has a broad scope that focuses on new discoveries in cellular and molecular immunology. Over the course of the year, Discovery Immunology has reached several important milestones, including achieving indexing with the Directory of Open Access Journals (DOAJ). We also launched the journal's first special collection, focused on checkpoint blockade.

Our focus for the next year is to continue building the reach and impact of the journal through publishing high-quality articles describing novel mechanisms of the immune response.

Supporting research consortia

Under our updated strategy, a new area of our work has been to support national and topic-specific research consortia efforts relevant to immunology. By championing investment in immunology and a 'team science' approach, we aim to use our skills to support cross-sector collaboration efforts to drive forward immunology research faster and more effectively. We have built on our initial success this year by providing a variety of services to support five national research consortia – National Core Studies Immunity, UK Coronavirus Immunology Consortium, CARINA (Catalyst Reducing ImmuNe Ageing) Network, SIREN (SARS-CoV-2 Immunity and Reinfection EvaluationN) study and STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing).



The National Core Studies (NCS) programme was established by the Government Office for Science in summer 2020 to ensure critical questions around COVID-19 could be answered quickly and effectively. The Immunity programme, led by Professor Paul Moss and funded by UK Research and Innovation (UKRI), funded studies that increase our understanding of immunity against COVID-19 and the role that vaccines play in this.

Building on our successful support through the previous 12 months, the BSI continued to run the UK COVID Vaccine Research Hub (www.covidvaccineresearch.org), a highly successful website set up for the public, policymakers and researchers to provide the latest information on COVID-19 vaccine research in the UK. We also ran the Patient and Public Involvement Panel for the consortia, which as well as ensuring the expertise and viewpoints of the public contributors were fed into the research agenda, also included developing a training programme for NCSi researchers and sharing best practice on how to successfully embed PPI in immunology research. Finally, we also supported NCSi researchers in communicating their work to policymakers, the media and the public in an accessible manner to maximise its impact and reach.



The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a project funded by the Medical Research Council and Biotechnology and Biological Sciences Research Council (BBSRC) and supported by the BSI. The network aims to establish a UK-wide inclusive platform to enhance collaboration and foster knowledge exchange around immune ageing as well as increasing the profile of the research area.

This has been a year of growth for the CARINA network, which now has over 90 members and has delivered a number of initiatives to build the network's capacity and output. We have run several in person and virtual all full network meetings, with a particular focus on facilitating cross-sector collaborations and gaining a shared consensus of the key research questions within immune ageing. CARINA's Early Career Forum is at the heart of their activity and have met regularly for spotlight and talks and development discussions. In addition, ECRs have been able to access free training in bioinformatics. CARINA has also successfully brought network members together to formulate innovate collaborative grant proposals focusing on developing biomarkers for immune frailty.

Keeping members informed

The BSI works hard to ensure good communication channels with our members, the wider immunology community and the public informed about our activities and about developments in immunology in the wider world. The popularity of our website continues with 2.11 million page views this year and 1.10 million unique users.

**2.11m
page views**

**1.10m
unique users**

BiteSized Immunology, our online resource designed to form a comprehensive guide to the immune system continues to be popular with six of the top ten most read pages. The BiteSized Immunology: Experimental Techniques: Enzyme-linked immunosorbent assay (ELISA) beat the BSI homepage to become the most visited website page of the year attracting 106,422 page views.

Our social media channels continue to grow in importance as a way of engaging with our membership and the wider world at a more immediate level, to interact with our supporters and spread the word about our work and the wonders of immunology. Across all channels, our social media posts were seen over 5.5 million times.

Championing careers

The BSI provides several grant schemes to our members to support their work and their career development. These include a variety of activities – from covering the travel costs to conferences, to providing financial support for carers, support for public engagement initiatives and those that promote diversity and inclusion within immunology. We are very proud of the range of support we have been able to provide to members over the last 12 months.

**£230k grants
awarded**


**313
members
supported**

Projects supported through our Equality, Diversity and Inclusion Activity Grant include:

- An EDI summer school
- A project to celebrate black female scientists
- A workshop exploring sex-based differences in the immune system

Career Enhancing Grants

Supporting current and future generations of immunologists throughout their careers is a vital part of our mission. This year has seen our Career Enhancing Grants go from strength to strength to support even more BSI members to reach their career goals. The scheme provides flexible financial support of up to £5,000 to allow individuals to build their skill set and advance their professional development.



Mentoring scheme

Our highly successful mentoring scheme brings together senior scientists with early career researchers to assist the next generation of immunologist with career development and progression. The popularity of this scheme has flourished in recent years with a steady stream of applicants both mentors and mentees and many stories of successful career progression from past participants.

Clinical immunology training days

We partner with the Association of Clinical Pathologists (ACP) to run clinical immunology training days aimed at medical trainees in immunology and allergy, and immunology clinical scientists preparing to sit the Royal College of Pathologists in immunology exams.

By working together, the ACP and BSI ensure the continuous delivery of these highly valued training sessions, helping to create a new generation of immunology-aware and informed clinicians and clinical scientists across the NHS to improve the care and treatment of patients with immune-mediated disease. This year saw a return to in person training events around the country, complimented with additional online sessions to cover the broad spectrum of the curriculum. The training events themselves are consistently ranked as excellent by attendees who value the targeted content.

Training

This year, as part of our strategy to increase our careers offering, we launched a new training function to provide tailored and innovative training to meet the needs of both immunologists, helping them keep their skills up to date and relevant, and non-immunologists, who want to understand the basics of the discipline to help in their jobs. This year, we launched two training offerings in bioinformatics and PPI training; however, we have lots of plans in the pipeline for additional courses – watch this space for more information!

Bioinformatics

This year, we launched a new training programme in bioinformatics, which has been developed and is delivered by Glasgow Bioinformatic Core. It aims to equip wet-lab immunologists, biologists and other life scientists with the skills and confidence to perform their own bioinformatic data analysis. Bioinformatics is now a potent driver of scientific development and an area where there is currently a significant skills gap within immunology. We offer a range of courses, suitable for complete beginners through to advanced practitioners. Through these highly rated courses, our aim is to provide affordable access and high-quality training in this essential skill to the current and future generations of immunologists.

**95 people
trained**

**Lecture delivery
9.63/10**

**Session content
9.63/10**

Training in Patient & Public Involvement

As part of our work on National Core Studies Immunity, we teamed up with five of our public contributors from that project to co-design an online course for researchers on how to involve the public and patients in their research, and how to better understand the mindset and approach needed for effective and inclusive involvement. During the course, researchers were able to hear directly from PPI representatives as well as allowing for peer-to-peer learning through sharing experiences and case studies of successful involvement.

Confidence in building rapport and relationships with public contributors increased from 48% before the course to 92% afterwards. Similarly, confidence in giving value to patient and public contributors increased from 9% before the course to 93% after the training.

Honorary members

Our honorary membership scheme recognises individuals who have made an outstanding contribution to immunology and/or to the Society. At BSI Congress 2022, we were delighted to award Lifetime Honorary Membership to two members:

- Professor Faith Osier (Imperial College London)
- Professor Ian MacLennan (University of Birmingham)

BSI Immunology Awards 2023

In April 2023, we revealed the winners of our inaugural BSI Immunology Awards. These awards were created to champion the remarkable achievements of individuals and teams working across the spectrum of immunology to drive excellence in our discipline.

We celebrated the awards at our 'Transforming the immunology landscape' event, which was an opportunity for the immunology community to come together to hear about the extraordinary work being undertaken by their peers and discuss future challenges and opportunities across the sector.

Eleven winners in eight categories were announced at a ceremony as part of our 'Transforming the immunology landscape' event. The event was an opportunity for the immunology community to come together to hear about the extraordinary work being undertaken by their peers and discuss the future challenges and opportunities across the spectrum of immunology research and application.



Congratulations to our Winners!

BSI Outstanding Ambassador for Immunology Award –
Professor Danny Altmann, Imperial College London
Dr Victoria Male, Imperial College London

Outstanding Contribution to the BSI Award –
Professor Gary Entrican, University of Edinburgh

BSI Research Excellence Award –
Professor Lucy Walker, University College London

BSI Early Career Research Excellence Award –
Dr George Robinson, University College London

BSI Outstanding Team Award –
Northern Ireland Multiple Sclerosis Research Network,
Queen's University Belfast / Belfast Health and Social Care Trust

BSI Diversity and Inclusion Award –
Tomi Akingbade, University of Cambridge
Dr Donald Palmer, Royal Veterinary College

BSI Public Engagement Award –
Professor Sheena Cruickshank, University of Manchester

BSI Immunology Teaching Excellence Award –
Dr Sophie Rutschmann, Imperial College London
Dr Tom Wilkinson, Swansea University

Catalysing change

Public engagement


Our public engagement work over the last 12 months has focused primarily on vaccines. We have used a wide variety of methods and routes to engage with different communities to understand and answer their questions around vaccination.

Resources for engagement

We have continued to develop a range of engagement resources around vaccines, including updating our highly rated comprehensive 'Guide to COVID-19 vaccinations' and creating an infographic to explain the importance of booster COVID-19 vaccines.

We also significantly updated our 'Guide to childhood vaccinations' which explains how vaccines work and provides latest information on the UK immunisation schedule, along with developing a new infographic about the polio vaccination campaign in London to encourage parents to catch up on their child's vaccines.

We launched a new 'Guide to vaccinations for adults over 65' to inform adults aged 65 and over about the different vaccines they are eligible for in the UK and answer common questions. This guide was developed in partnership with the CARINA Network and is sponsored by the UK SPINE Knowledge Exchange Network.



We've been working with the EFIS Vaccine Task Force members to translate some of our infographics about how vaccines work into different languages, including Turkish, to make information accessible to diverse communities across Europe.

Additionally, our cancer immunotherapy darts activity featured in the 2023 British Science Week activity packs that were shared with primary schools and community groups across the country.

#VaccineConversations

Empowering our members to engage with their family, friends and communities to have meaningful conversations about vaccines has continued to be a core part of our public engagement work. We held our annual online vaccine engagement day and encouraged members to use their expert voices for a day of education and celebration to champion the critical role of vaccines. These conversations from trusted individuals are incredibly important in strengthening public understanding and helping people make informed decisions about vaccination.

This year, we were excited to return to events in person on a more regular basis, using our interactive activities and resources to engage with all ages about the different components of the immune system, the importance of vaccination and herd immunity. We participated in the Cambridge Big Biology to engage with school-aged children and families, the Science Museum 'Lates' aimed at adults over 18 and the Lambeth Country Show to reach communities in London who wouldn't normally engage with immunology.

Supporting our members' public engagement activities

Our public engagement grant scheme had a revamp this year and was renamed the Communication & Engagement grant, offering our members financial support to develop and deliver their own public engagement activities. We funded twelve successful applications, including a public engagement stall at Glastonbury festival around the immune system and gut microbiome, showcasing the importance of immunology in health and disease. The stall interacted with an estimated 1,200 people over the weekend and overall, feedback was very positive with visitors expressing their interest in immunology and microbiome research.

Partnership for maximum impact

To build public trust and confidence in vaccines, it's important that we work with a variety of organisations to increase our reach into different communities. We partnered with the London Borough of Bexley to create short videos featuring BSI members answering common questions about different aspects of childhood vaccinations, which are played in GP surgeries, shared across community groups and featured online. We also supported NHS England with their social media 'fact cards' answering common questions about COVID-19 vaccine boosters targeted for Black African, Black African Caribbean and Asian communities. These were also used to engage local and national community groups, for example shared by the British Islamic Medical Association (BIMA) and mosques in their WhatsApp groups. We also collaborated with NHS England to develop a new animation about routine vaccinations aimed at families. The animation is shared widely on YouTube and social media. Furthermore, we joined IUIS to celebrate International Day of Immunology for which our president featured in a short public-facing video around the theme of "Immunology talks to public health".

We recognise the importance of sharing best practice of public engagement around vaccines and were invited to present at the UK Health Security Agency conference in late October. This key event brought together experts from local government and public health and was an excellent opportunity to showcase the impact our work has had to a large audience.

Training community champions to have effective vaccine conversations

There has never been a more important time for immunologists to engage with the public about vaccinations by listening to and addressing questions and concerns. We expanded our public engagement work around training community champions to have effective conversations about vaccinations. This year, we collaborated with Birmingham City Council on a programme to train 'vaccine champions' within local community groups to have effective conversations with their peers about vaccinations, including COVID-19, childhood, HPV and flu vaccines.


The training was co-designed with the local authorities' public health teams and their residents, addressing specific questions and key concerns raised by participants and their communities. The programme consisted of accessible online sessions for one hour each week over four weeks. The sessions were led by BSI members who have specialist knowledge of vaccines and honed skills in engagement and communication.

The sessions focus on building understanding of how vaccines train the immune system, as well as developing skills in listening to and answering common questions and sometimes complex worries. Sessions are also supported by our public-friendly resources about vaccines that participants can use and signpost people to.

After completing the training, 100% of community champions in Birmingham strongly agreed or agreed that they felt informed and knowledgeable about vaccines as well as confident to have effective conversations about vaccines. Encouragingly, all community champions reported an increase in the number of people they regularly talk to about vaccinations.

Patient and public involvement

Following our delivery of patient and public involvement (PPI) within the UK Coronavirus Immunology Consortium (UK-CIC), we published our experiences as a paper in the journal Research Engagement & Involvement detailing the positive impact of PPI in the UK-CIC. The paper was co-authored with public contributors who worked with us in the PPI panel within UK-CIC and shared our experiences of running the project and lessons learnt. UK-CIC brought together laboratory-based scientists and clinicians with the experience and unique perspectives of patient and public contributors. The PPI panel within UK-CIC provided a platform for regular two-way conversations with researchers to address key questions about the implications of the research as well as discussions about what was important to the public and patient groups.



This year, we continued to support the National Core Studies Immunity programme and led on the PPI element of the project. We hosted a free public webinar about the research being undertaken to study the immune response to COVID-19 boosters, which included opportunity for the public to submit questions they had around COVID-19 vaccines.

We were proud to launch a new report in association with National Core Studies Immunity entitled 'Patient and public involvement in COVID-19 research: bridging the gap between theory and practice'. The report explored the impact of PPI in COVID-19 research with the aim of encouraging more research teams to consider involving patients and the public in their work, and to provide practical examples of how this can be done to great effect. It was produced with substantial contribution from a group of patients, carers and members of the public and described how research teams working as part of National Core Studies Immunity involved patients and the public in their work, as well as what it means to involve public contributors in research more generally.

Policy highlights

This year, the Society has continued to use our powerful voice to advocate for immunological science and health, ensuring the voice of immunologists is heard loud and clear in public debates and that policymakers have access to the latest immunological thinking. With our dynamic approach, working in partnership with BSI members and with our COVID-19 Taskforce, we have played a strong role in both ensuring the expert voice of immunologists is represented in public debate and how the lessons learnt from the COVID-19 pandemic response can be brought to wider areas of health research.

Engaging with stakeholders

Through our policy and public affairs work, we aim to engage with policymakers and stakeholders to ensure the viewpoint and interests of immunologists are represented in public debate. Over the past year, we have:

- Responded to a number of policy consultations on topics including the future of cancer therapies, prevention strategies in healthcare, misinformation and trusted voices, NHS vaccination strategy consultation, and people and skills in STEM
- Participated in a number of Parliamentary events run by the Royal Society of Biology including Voice of Young Science and Parliamentary Links Day
- Seen several of our response themes adopted in the publication of the Cabinet Office's new national biosecurity strategy document, including stepping up surveillance efforts, continuing investment in vaccines and therapeutics, and building and strengthening links with our international partners.
- Seen the House of Commons' Health and Social Care Select Committee's Inquiry on Prevention choose our proposal 'Vaccinations' as a workstream for this inquiry to determine and advise the Government on how the UK can remain at the forefront of global vaccination policy
- Seen the BSI's community vaccine engagement work highlighted in the oral evidence sessions of the House of Commons Digital, Culture, Media and Sport Select Committee's enquiry on 'Misinformation and trusted voices' as an exemplar of why learned societies are valuable partners in the fight against misinformation.
- Had almost 50 parliamentary questions answered on a wide range of topics including Horizon Europe, barriers to pursuing careers in scientific research and support for predictive vaccinology research.
- Our proposal to the National Screening Committee on the benefits of screening for human T-lymphotropic virus type 1 (HTLV) in high-risk populations has led to a wider consultation to explore this proposal further.
- Took part in two roundtable events on MMR vaccination and Horizon Europe

Enablers

To deliver our ambitious strategic aims, we need to maintain the BSI as a sector-leading organisation. We will do this by:


- Creating a larger and more diverse engaged membership
- Embedding quality, diversity and inclusion in all our activities
- Ensuring the Society's financial sustainability

Enabler - membership

Our membership is the foundation of our Society. We are ambitious in what we want to deliver for immunology and for our members. As the discipline of immunology continues to grow and evolve, we aim to evolve too to ensure we engage with, support and are relevant to immunologists from across the spectrum of our community. As the largest professional immunology society in Europe and third largest in the world, we aim to stand shoulder to shoulder with our members to support and champion the discipline of immunology to drive scientific discovery and make a positive impact on health.

To continue supporting our diverse and ever-growing community, we revamped our membership categories in July 2022. Five categories grouping some of the most common areas in which our members work were introduced. We will continue to provide tailored benefits for each career stage of each category.

Our new membership categories showcase the different sectors that encompass our vibrant community. We also expanded the criteria for the Early Career Membership to include anyone in the first seven years from receipt of their PhD. A new category for those retired from full-time employment was also introduced. The BSI continues to offer concessionary discounts and free membership to various groups.



Providing the best service for our members

One of our key aims is to ensure that increase our support and engagement with our members from all sectors and at all career stages. To support this work, this year we carried out a major project to embed a new membership management system to allow us to provide better, more joined up and holistic support and service for our members. Alongside this, we also upgraded our website to increase functionality and accessibility as well as making it easier to navigate. Both projects have now been successfully implemented resulting in a seamless experience for our members to better interaction with our services.

BSI Clinical Immunology Professional Network

Following the successful merger between the British Society for Immunology (BSI) and the UK Primary Immunodeficiency Network (UKPIN) in early 2023, we have established the BSI Clinical Immunology Professional Network (BSI-CIPN) – a new network championing clinical immunology within the BSI.



In combining the expertise of the BSI and UKPIN, the network aims to foster closer links between clinical practitioners and basic scientists and strengthen the voice of clinical immunology in policy and public arenas. The BSI-CIPN will also share best practice through a range of resources and activities, including dedicated events, clinical sessions at BSI Congress, development of clinical guidelines, training provision and much more. By providing this strong platform for UK clinical immunology, our aim is to improve care for patients.

The activities of the network are overseen by the BSI-CIPN Steering Group, chaired by Dr Sinisa Savic, supported by Deputy Chair Dr Suzanne Elcombe. The network welcomes members from all aspects of clinical immunology including clinicians and trainees, nurses, healthcare scientists and pharmacists.

Having spent this year embedding the network within wider BSI activities, we now have an eye on the future and an exciting programme of activities planned for the next 12 months. Watch this space for more details.

Immunology Nursing Competency Framework

In May, we were delighted to publish the first ever competency framework for immunology nursing in the UK to advance patient care and nursing practice. Immunology nursing plays a vital role in the healthcare system, providing essential support to individuals with complex and diverse immune-related conditions, and demanding a highly skilled and competent nursing workforce. By combining underlying immunology knowledge with clinical best practices and the latest therapeutic advances, this framework provides a comprehensive roadmap for mastering the skills and knowledge required in immunology nursing, covering all career grades from newly entering into the speciality to undertaking nurse-led clinics. Our aim is for this framework to be flexible and to empower immunology nurses to stay abreast of advancements while working innovatively to improve standards of care for patients.

BSI-CIPN meeting

To celebrate the launch of the BSI-CIPN, we held a one-day conference in tandem with the BSI Congress to bring together the clinical immunology community on the topic of 'Expanding horizons within clinical immunology: Redefining the scope of clinical practice'. The successful event brought together over 100 professionals working in clinical immunology to discuss diverse topics such as COVID-19 and primary immunodeficiencies, the new UK perioperative anaphylaxis network as well as learning more about the aims and ambitions of the BSI-CIPN.

Immunology News

Members in the UK can receive a printed copy of our quarterly membership magazine, *Immunology News*, with online access around the world. *Immunology News* amplifies the voice of our membership and highlights how we're supporting our members and representing immunology on a wider stage.



Over the last year editions featured new BSI membership categories, women in immunology, the BSI's new Bioinformatics training courses, BSI and UKPIN merger and the creation of the BSI-CIPN, training community vaccine champions, an international BSI's member's perspective, the 2022 BSI Summer School and the launch of our new journal *Discovery Immunology*.

There were also interviews with the outgoing and new Presidents, Prof Arnie Akbar and Prof Tracy Hussell.

This year also included a recap of highlights from BSI Congress 2022 and highlights from the celebration of the immunology community at the inaugural BSI Immunology Awards.

Corporate members

We would like to thank our corporate members whose continuous support enables us to undertake our work



Enabler - Equality, diversity and inclusion

The BSI wants diversity and inclusion to be at the heart of the ethos of our community. This year, we have continued to build on the promises laid out in our 'Diversity and Inclusion Framework', which outlines our commitment to how we are going to work with our members and community to ramp up our equity, diversity and inclusion work and respond to members' needs. By building on past and ongoing activities, this framework set out our long-term plan of action for diversity and inclusion at the BSI.

This year, we have made significant steps forward in our EDI commitment, carrying out an organisational wide review of how EDI is embedded within our activities and how staff are supported in delivering these and developing their knowledge of best practice in EDI. We have also engaged much more deeply with our wider membership around understanding their views of the BSI's role in supporting EDI within immunology, what we are doing well and what we could do better. In September, we held two focus groups with a wide cross section of our membership and received some incredibly useful feedback as well as ideas and suggestions for future activities that we are taking forward. Watch this space! We also ran a session at BSI Congress on EDI, highlighting some successful case studies from our Equality, Diversity and Inclusion Activity Grant scheme as well as getting members' feedback on the implementation of our Diversity and Inclusion Framework.

Finally, we have been engaging deeply with the wider scientific community to spread best practice on how we developed our framework and to learn from their experiences of similar activities.

Enabler - Financial sustainability

Income diversification

To deliver our ambitious strategic plans, we need to maintain the BSI as a sector-leading organisation, and one of the crucial enablers to do so is our financial sustainability. While traditionally we have relied heavily on our journal income to fund charitable activities, our shift to bring in new long-term and stable income sources is now well under way. The development of new income streams is never a quick process as there is often a delay between investment and return, requiring the use of reserves. However, our strong reserves have been built up for exactly this purpose – to support the organisation through this transition – and their use is now carefully planned.

Consolidating our approach

Last year, we reported on changes to our journals with the aim of moving our financial reliance away from traditional subscription journals to develop a modern publishing portfolio that also meets the needs of our members and wider immunology community. This work is now well underway, and this year saw the growth of our two new Open Access journals, Immunotherapy Advances and Discovery Immunology, which are proving popular additions to the BSI portfolio. Both journals have met key milestones this year on their journey towards gaining an impact factor and stabilising our future journals income.

Our new activity to provide support to wider immunology research efforts is also paying dividends and we have built up a strong reputation within the sector for assisting the smooth running, effectiveness and impact of large research consortia. Prestigious projects we have worked on over the last 12 months include UK Coronavirus Immunology Consortium, SIREN (SARS-CoV-2 immunity and reinfection evaluation) study, National Core Studies Immunity, the CARINA (Catalyst Reducing ImmuNe Ageing) Network and STRAVINSKY (Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing). Our participation in this type of funded project continues to be an important source of income while allowing us to meet our wider goal of supporting the national immunology research effort.

New endeavours

This year has seen the launch of several new projects, which fulfil our goals of making a positive contribution to the immunology sector while also diversifying the BSI's income. Chief among these has been the launch of a BSI training function to support immunologists and the wider research community to keep their skills up to date and relevant. Our first training offering on bioinformatics, delivered in partnership with Glasgow Bioinformatic Core, has proved hugely popular, with exceptionally positive feedback, and provides vital training in a growth area for immunology. We also piloted a training course for researchers in public and patient involvement, which we hope to roll out further next year. These courses, along with several new offerings in pipeline which particularly focus on the clinical sector, mean the BSI is well on our way to establishing ourselves as a leading training provider in the immunology sector.

We are also enhancing our partnership and sponsorship areas of work with industry, establishing mutually beneficial routes for collaboration to highlight, celebrate and champion the immunology sector, which has been core to our strategic development of this area of work. Notably among these is the launch of our new Immunology Awards ceremony which brings together leaders from across the immunology sector to celebrate the potential of immunology to make positive contributions to wider society and public health.

Structure, Governance and Management

Charitable status and administrative details

The Society was registered as a charity in 1966 (Charity number 1043255) and incorporated in England and Wales as a company, limited by guarantee (Company number 03005933). The Society's registered address is 9 Appold Street, London EC2A 2AP. It has no share capital and the liability of its members is limited to a sum not exceeding £1. The Society's governing document is the Memorandum and Articles of Association, which was amended on 7 December 2016.

It is also a registered charity in Scotland (Charity number SC047367).

Board of Trustees

The Trustees are company directors for the purposes of the Companies Act and charity Trustees for the purposes of the Charities Act 2011. The current trustees, and any past Trustees who served during the year are listed on page 56.

The Trustees are responsible for directing the Society's activities and for overseeing the management of the affairs of the Society, they delegate the day to day management of the organisation to the chief executive and the senior management team. The Board acts on advice and information from regular meetings with the chief executive and the senior management team.

As part of their induction process, Trustees spend some time with the chief executive and senior management team. They are provided a trustee resource pack containing the history of the Society and key information they require to fulfil their duties as Trustee, they are also offered training for new Trustees.

The success of the Society belongs in part to the large number of people who generously volunteer their time to add their experience to our collection of committees, we thank you all.

Finance Sub Committee

The Finance Sub Committee ensures the system of internal control is satisfactory to deliver regulatory compliance, financial probity, value for money, challenge of financial plans, budgets and financial statements, oversight of the annual financial audit, review of investment policy and performance, review of reserves policy, and CEO and staff remuneration.

Nominations Committee

The BSI's Nominations Committee has general oversight concerning the structures and effectiveness of BSI Board of Trustees, committees, advisers and observers. It is also responsible for nominating individuals to represent the views of the BSI on external committees and to identify BSI members to nominate for external awards.

Member Representative Forum

The Membership Representative Forum represents a diverse mix of immunologists from different career stages, backgrounds and geographic locations, it is the BSI's 'think tank' and the place where issues and ideas that are of importance to the Society and its member are raised, discussed and developed.

Congress Committee

The Congress Committee is responsible for the planning and delivery of the BSI's flagship event, BSI Congress, which takes place two out of every three years. It reviews and approves the scientific programme for Congress.

BSI-CIPN Steering Group

The BSI-CIPN Steering Group directs the activities of the BSI-CIPN. The group consists of both elected (from the BSI-CIPN members) and co-opted immunology professionals (chosen because of their roles in other key organisations).

Group structure

The Society has two wholly owned subsidiaries:

BSI Trading Limited is registered in England and Wales under company registration number 010201739. Its principal activity is to manage the corporate membership, sponsorship, exhibition and other trading activities for the Society.

The United Kingdom Primary Immunodeficiency Network (UKPIN) is a registered charity (1164466) and a company registered in England and Wales (09273983). The principal activity is the advancement and support of clinical immunology, especially the health among those with primary immunology deficiency disorders and advancing education in PID and related subjects. These activities have been transferred to the Society's Clinical Immunology Professional Network (BSI-CIPN).

Financial Performance


The BSI continued our transition period following the changes to our publishing portfolio. The annual net deficit reduced by 35% from £0.63m last year to £0.41m this year. The operating deficit before investments were better than budget.

The BSI recorded its highest ever income reaching £2.45m, 11% higher than 2022.

Income



Publishing income remains the BSI's largest source of income, however it continued to fall from 41% of total BSI income in 2022 to 31% this year. This fall was offset by increases in income from Congress and grants and donations.



Congress 2022 attracted a record number of delegates and increased income from exhibition space hire and sponsorship.

The Society continued our success obtaining funding for our work supporting immunology research. Total grants received were over £0.2m for the second consecutive year. Total donations of £0.21m were received in 2023. This includes £0.18m from UKPIN following the merger with the BSI during the year.

The newly launched BSI-CIPN held its first meeting in December 2022, this attracted over £100k of sponsorship income. It is anticipated that the BSI-CIPN will assist in creating partnerships with industry leading to exciting projects in future years.

In their second year, the BSI funded career enhancing grants of £121k. This continues to be an important source of career support to our members.

Increased sales of exhibition space and sponsorship at Congress helped push BSI Trading Limited to an annual profit of £0.49m (2022: £0.34m). This was gifted to the society.

The United Kingdom Primary Immunodeficiency Network (UKPIN) posted a loss of £5k for the period.

The Society is in a transition period following the reduction in journal income. The Society is focusing on developing new income streams; however, this will require investment from our reserves. During this period, we are forecasting costs to exceed income over the next few years until the new income streams start generating significant levels of income.

Investment policy and performance

The Society operates an investment policy to provide income and generate capital growth. The Society is a long-term investor and the value of its investments remains significant above its original investment.

UK events including the 2022 mini budget, the high level of inflation together with global events such as the Russian invasion of Ukraine created another challenging year for investments.

As planned the BSI commenced our programme of drawdowns from investments as we invest in new sources of sustainable income. During the year £1m was withdrawn from our investments to help meet the BSI's cash requirements.

Funds are invested with abrdn (formerly Aberdeen Standard Chartered) with a long-term objective to generate a capital return of 3% more than inflation over a three year rolling period. As noted above performance was challenging this year resulting in a small net loss of £0.007m (2022: £0.51m gain). The value of the portfolio fell by £0.94m (2021: fall of £0.31m) because of the drawdowns. On 30 June 2023 investments were valued at £3.30m (2022: £4.26m).

The Finance Sub Committee is responsible for reviewing investment performance and policy.

Reserves policy

The BSI operates a risk-based approach to reserves to ensure the BSI holds the most appropriate level of reserves to cover potential risks and to fund invest in new income sources securing the BSI's long term financial health.

The risk register is reviewed annually with monetary values allocated to specific risks. This value is added to the total of restricted and designated funds. A provision for unknown risks (to give cover for those risks of which the society is not yet aware) is then added to produce the required reserves level. The calculation of the required reserves level is performed on an annual basis.

The latest review resulted in total required reserves of £3.78m (2022: £3.76m). On 30 June 2023 total reserves were £3.90m, (2022: £4.31m), this was £0.12m more than the total required reserves. The charity held free reserves (unrestricted reserves less fixed assets) of £2.95m (2022: £3.25m). Details of restricted funds can be found in note 15 of the accounts with details of designated funds in note 16.

Pay policy

The Society's pay policy aims to ensure that all employees are paid at least the market median for their roles with the ability of high performers to move towards the upper quartile.

Salaries, including the Senior Management Team, are reviewed by the Finance Sub Committee with recommendations for the annual pay rise proposed to the wider Board of Trustees for approval as part of the annual budgeting process. The salary of the Chief Executive is reviewed annually by the Board of Trustees.

To increase transparency the Society's is voluntarily reporting its gender pay gap. Calculated in June 2023 the Society's mean gender pay gap is 23% (June 2022: 32%). The pay gap indicates that while 75% of employees are women (2022: 72%), most men are in management roles. The Society employs more women in each of the quartile pay bands.

The Society strongly supports equal pay, with individuals with the same responsibilities being paid the same irrespective of gender.

Risk management

Good risk management is fundamental to the continued work and sustainability of the Society. We identify and manage risks that could adversely impact the achievement of our strategic purpose and determine the calculated risks we need to take to succeed.

The Society operates a formal framework for the management of risk, taking the view that risk can be positive (opportunity) or negative (threat). The Society operates a risk register incorporating strategic, operational and compliance risks, which are informed by the Society's strategic objectives, performance, voice of our stakeholders, regulatory environment and analysis of the external environment.

The Board delegates day-to-day responsibility for risk management to the Senior Management Team, who are responsible for identifying and evaluating risks to their areas and activities implementing appropriate controls for ongoing mitigation and monitoring.

The Financial Sub Committee reviews the management of risk in detail at each meeting and the Board reviews the Society's strategic and compliance risks twice a year.

The principal risks and uncertainties facing the society and the mitigations that we have put in place are as follows:

| Risk: short term | Risk response |
|--|--|
| Development of new surplus generating training function | <p>The Society has performed detailed market analysis and is focussing development of training in areas where demand has been identified.</p> <p>The BSI are working with partners to develop and market courses. Regular review of delegates numbers and experiences are performed to ensure courses are relevant.</p> |
| Unable to recruit the right people | <p>Upon coming vacant all roles are reviewed to ensure they are relevant, job descriptions are reviewed and updated to ensure they are clear. Roles are benchmarked to market rates and we conduct a transparent and inclusive recruitment process.</p> |
| Risk: long term | Risk response |
| Inflation – rising costs | <p>The Society regularly reviews value for money from our suppliers and potential impacts on future sustainability, proposing action as required.</p> |
| Failure to find new sources of long term sustainable income | <p>The Society is proactively looking for new funding opportunities:</p> <ul style="list-style-type: none"> ▪ Working with partners and corporate members to develop existing and new sources of income ▪ Developing a programme of training courses with partners including University of Glasgow |
| <p>Loss of significant devaluation of investments</p> <p>A devaluation in the value of investments would result in a reduction of reserves available to use by the Society.</p> <p>Investments could be impacted by sudden unforeseen global events</p> | <p>The Society</p> <ul style="list-style-type: none"> ▪ Reviews investment performance during each Financial Sub Committee meeting ▪ Communicates regularly with our investment managers, especially through times of significant volatility |

Fundraising statement

Although the Society does not actively fundraise from members, occasional donations are received. The Society applies best practice in the tone of its communications and the accuracy of its data to minimise the pressures on supporters. The Society applies best practice to protect supporters' data, never sells or swaps it and ensures that communication preferences can be changed at any time. The Society commits to react to and investigate any complaints received, to learn from them and improve its service. During the year, the Society received no complaints about its fundraising activities.

Future plans

During 2023-24 the Society will focus on:

Connected community

- Delivering a successful Congress 2023
- Delivering the first two-day BSI-CIPN conference

Championing careers

- Successfully increase the careers support the BSI provides to members

Catalysing change

- Continue and expand the BSI's successful partnership work
- Expanding the BSI's PPI activities through support of and inclusion in national research consortia

Enabler - membership

- Launching targeted marketing campaigns to drive membership growth
- Grow membership of the BSI-CIPN

Enabler - Equality, diversity and inclusion

- Collecting benchmark EDI data on BSI committees and creating a plan to further embed EDI in BSI activities

Enabler - Financial sustainability

- Income diversification is a key priority: expanding current income generating activities and identifying and developing new sources of income

The Senior Management Team and the Trustees continue to assess all significant risks, in the immediate, medium and longer term.

Trustees' responsibilities

The Trustees (who are also directors of British Society for Immunology for the purposes of company law) are responsible for preparing the Trustees' report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Group and Society and of the income and expenditure of the Group and Society for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland; and
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume the charity will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Group and Society and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and Society and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.


Each of Trustees confirm that:

- so far as the Trustee is aware, there is no relevant audit information of which the Group and Society's auditor is unaware; and
- the Trustee has taken all steps that he/she ought to have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the Group and Society's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

The Trustees are responsible for the maintenance and integrity of corporate and financial information included on the Society's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the Trustees and signed on their behalf by:



Tracy Hussell
BSI President

Date: 18 October 2023

Independent Auditor's Report to the members and trustees of the British Society for Immunology

Opinion

We have audited the financial statements of the British Society for Immunology for the year ended 30 June 2023 which comprise the Group Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the group's and the parent charitable company's affairs as at 30 June 2023 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the trustees' annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
certain disclosures of trustees' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit; or
the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council

We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.

We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.

We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.

Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.

Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

Moore Kingston Smith LLP

Date 7 December 2023

Neil Finlayson (Senior Statutory Auditor)
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

9 Appold Street
London
EC2A 2AP

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

British Society for Immunology
Consolidated Statement of Financial Activities
Year to 30 June 2023

| | | Unrestricted funds | | | | |
|-----------------------------------|------|------------------------|---------------------------|---------------------------|------------------------|------------------------|
| | Note | General funds £'000 | Designated funds £'000 | Restricted funds £'000 | Total 2023 £'000 | Total 2022 £'000 |
| Income from: | | | | | | |
| Grants and donations | 2 | - | - | 425 | 425 | 280 |
| Investments | 3 | 132 | - | - | 132 | 151 |
| Charitable activities | 4 | | | | | |
| Membership | | 162 | - | - | 162 | 160 |
| BSI-CIPN | | 105 | | | 105 | - |
| Partnership work | | 105 | - | 15 | 120 | 136 |
| Congress | | 643 | - | - | 643 | 512 |
| Meetings and events | | 83 | - | - | 83 | 59 |
| Journals | | 749 | - | - | 749 | 913 |
| Training | | 28 | - | - | 28 | - |
| Total income | | 2,007 | - | 440 | 2,447 | 2,211 |
| Expenditure on: | | | | | | |
| Raising funds | | | | | | |
| Investment management fees | | 35 | - | - | 35 | 41 |
| Cost of raising funds | | 12 | - | - | 12 | 30 |
| Charitable activities | | | | | | |
| Membership | | 241 | - | - | 241 | 240 |
| BSI-CIPN | | 80 | - | - | 80 | - |
| Partnership work | | 147 | - | - | 147 | 133 |
| Congress | | 720 | - | - | 720 | 642 |
| Meetings and events | | 289 | - | - | 289 | 184 |
| Journals | | 370 | - | - | 370 | 370 |
| Training | | 35 | 59 | - | 94 | - |
| Education and Careers | | 64 | 136 | - | 200 | 198 |
| Diversity and inclusion | | 2 | - | - | 2 | 4 |
| National Research support | | - | - | 129 | 129 | 149 |
| Policy and Public Affairs | | 21 | - | 158 | 179 | 175 |
| Public engagement | | 72 | - | 38 | 111 | 118 |
| Communications | | 221 | - | - | 221 | 228 |
| International work | | 23 | - | - | 23 | 28 |
| Total expenditure | 5 | 2,333 | 195 | 325 | 2,853 | 2,540 |
| Net income (expenditure) | | | | | | |
| before gains (losses) on | | (326) | (195) | 115 | (406) | (330) |
| investments and transfers | | | | | | |
| Net gains/(losses) on investments | 12 | (7) | - | - | (7) | (305) |
| Transfers between funds | | 23 | (23) | | - | - |
| Net income/(deficit) | | (310) | (218) | 115 | (413) | (635) |
| Reconciliation of funds: | | | | | | |
| Funds brought forward | | 3,396 | 771 | 143 | 4,310 | 4,944 |
| Funds carried forward | | 3,086 | 553 | 258 | 3,897 | 4,310 |

There are no recognised gains or losses other than those recognised above. All activities are continuing.

The notes on pages 37 to 55 form part of these financial statements


British Society for Immunology
Balance Sheet
30 June 2023

| | | Group | | Charity | |
|--|----|--------------|--------------|----------------|--------------|
| | | 2023 | 2022 | 2023 | 2022 |
| Fixed assets | | | | | |
| Tangible fixed assets | 10 | 53 | 49 | 53 | 49 |
| Intangible assets | 11 | 79 | 93 | 79 | 93 |
| Investments | 12 | 3,299 | 4,259 | 3,306 | 4,259 |
| | | 3,431 | 4,401 | 3,438 | 4,401 |
| Current assets | | | | | |
| Debtors | 13 | 692 | 552 | 1,225 | 875 |
| Cash at bank and in hand | | 578 | 407 | 25 | 37 |
| | | 1,270 | 959 | 1,250 | 912 |
| Liabilities: | | | | | |
| Creditors: amounts falling due within one year | 14 | (804) | (1,050) | (788) | (1,003) |
| Net current assets | | 466 | (91) | 462 | (91) |
| Net assets | | 3,897 | 4,310 | 3,900 | 4,310 |
| Funds: | | | | | |
| Unrestricted funds | | | | | |
| General fund | | 3,086 | 3,396 | 3,089 | 3,423 |
| Designated fund | 16 | 553 | 771 | 553 | 771 |
| | | 3,639 | 4,167 | 3,642 | 4,194 |
| Restricted funds | 15 | 258 | 143 | 258 | 116 |
| Total | | 3,897 | 4,310 | 3,900 | 4,310 |

As permitted by s408 Companies Act 2006, the company has not presented its own income and expenditure statement and related notes. The company's loss for the year was £409,171 (21/22 FY: £631,850).

These financial statements have been prepared in accordance with the provisions applicable to the small companies regime.

These accounts were approved by the Board and authorised for issue on 18 October 2023 and were signed on its behalf by:



Tracy Hussell, President

British Society for Immunology
Consolidated Statement of Cash Flows
30 June 2023

| | 2023 £'000 | 2022 £'000 |
|---|---------------|---------------|
| Cash flows from operating activities: | | |
| <i>Net cash provided by operating activities</i> | (893) | (765) |
| Cash flows from investing activities: | | |
| Income from investments | 132 | 151 |
| Purchase of tangible fixed assets | (21) | (40) |
| Purchase of intangible fixed assets | - | (57) |
| Proceeds from the disposal of investments | 1,669 | 521 |
| Purchase of investments | (933) | (659) |
| Net cash used in investing activities | 847 | (83) |
| Change in cash and cash equivalents in the year | (46) | (848) |
| Cash and cash equivalents at 1 July 2022 | 637 | 1,485 |
| Cash and cash equivalents at 30 June 2023 | 591 | 637 |
| Net income for the period (as per the statement of financial activities) | (413) | (635) |
| Adjustments for: | | |
| Depreciation charge | 30 | 9 |
| (Gains) losses on investments | 7 | 305 |
| Investment income | (132) | (151) |
| (Increase) decrease in debtors | (140) | (422) |
| Increase (decrease) in creditors | (245) | 129 |
| Net cash provided by operating activities | (893) | (765) |
| Analysis of cash and cash equivalents | | |
| Cash at bank and in hand | 578 | 407 |
| Cash held by investment managers | 13 | 230 |
| Total cash and cash equivalents | 591 | 637 |

The notes on pages 37 to 55 form part of these financial statements

Notes to the financial statements

1 Accounting policies

The principle accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

Basis of preparation

The financial statements are prepared on a going concern basis, under the historical cost convention modified to include the recognition of listed investments measured at fair value, which is consistent with the prior year. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities ("The SORP"), the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

The British Society for Immunology ("The Society") meets the definition of a public benefit entity under FRS 102.

General information

The Society is a charitable company incorporated in England and Wales (company number 03005933) and is a charity registered in England and Wales (charity number 1043255) and registered as a charity in Scotland (charity number SC047367). The Society's registered address is 9 Appold Street, London EC2A 2AP.

Critical accounting judgements and key sources of estimation uncertainty

The preparation of financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group and Society accounting policies. In the application of the accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of revision and future periods if the revision affected current and future periods.

In the view of the Trustees, no assumptions concerning the future or estimation uncertainty affecting assets or liabilities at the balance sheet date are likely to result in a material adjustment to their carrying amounts in the next financial year.

Going concern

The financial statements are prepared on a going concern basis which assumes the Society and Group will continue to meet its liabilities as they fall due for a period of at least twelve months from the date of the approval of these accounts. The Trustees are monitoring the post pandemic impact on the Society and Group. This includes regular review of the impact on our members and resulting changes in focus of our activities to support them. Trustees review regular updates on performance against KPIs, rolling forecasts, the risk register and in depth financial reports.

Following the pandemic, the immunology community is busier than ever, attracting new funding to support its essential work to improve public health. This together with the holding of significant levels of cash and investments result in the Trustees considering the Society and the Group to be a going concern.

Notes to the financial statements

Income

All income is recognised once the Society and Group has entitlement to income; it is probable that income will be received and the amount of income receivable can be measured reliably. Income of the Society is, where applicable, included net of Value Added Tax (VAT) and is allocated to the period to which it relates, carrying forward that part of the income relating to future accounting periods.

Investment income is recognised on a receivables basis and when the amount can be measured reliably.

Expenditure

Liabilities are recognised as soon as there is a legal or constructive obligation committing the Society and Group to that expenditure, it is probable that settlement will be required and the amount of obligation can be measured reliably. Expenditure is recognised on an accruals basis as a liability is incurred, inclusive of VAT, which cannot be recovered.

Expenditure is allocated to a particular activity where the cost relates directly to that activity. The cost of overall direction and administration of each activity, known as "support costs" and comprising the salary and overhead costs of the central function is apportioned based on staff time attributable to Support costs also include governance costs, which comprise organisational administration and compliance with constitutional and statutory requirements. The allocation of support and governance costs is analysed in notes 7 and 8.

Employee benefits

Short-term benefits including holiday pay are recognised as an expense in the period in which the service is received.

Termination payments are accounted for on an accruals basis and in line with FRS 102.

The Society contributes to a Group pension scheme, the assets of which are administered by Royal London Plc. They are defined contribution schemes. All contributed costs are accounted for on the basis of charging the cost of providing pensions over the period when the Society and Group benefits from the employees' service. The Society and Group has no further liability under the scheme.

Leasing and hire purchase commitments

Rentals paid under operating leases are charged to the income and expenditure account on a straight line basis over the lease term. The Society holds no assets under finance leases or hire purchase contracts.

Tangible fixed assets

Tangible assets are stated at cost less accumulated depreciation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Depreciated is provided at 33% in order to write off each asset over its estimated useful life.

Intangible fixed assets

Intangible assets are stated at cost less accumulated amortisation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Amortisation is provided at 20% in order to write off each asset over its estimated useful life. Assets in the course of construction are not amortised.

Notes to the financial statements

Investments

Investments are a form of basic financial instrument and are initially shown in the financial statements at fair value. Movements in the fair value of investments are shown as net gains and losses in the Statement of Financial Activities.

Profits and losses on the realisation of investments are shown as realised gains and losses in the Statement of Financial Activities. Net gains and losses on investments are calculated between sales proceeds and their opening carrying values or their purchase price if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

The investment in the subsidiary undertaking is included at cost with provision being made for any permanent diminution in value.

Financial instruments

I) Financial assets

Basic financial assets, including trade and other receivables, cash and bank balances, are initially recognised at transaction value and subsequently measured at amortised cost. Other financial assets, including investments, are initially measured at fair value. Financial assets are derecognised when:

- a) the contractual rights to the cash flows of the asset expire or are settled, or
- b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or
- c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Cash at bank and cash in hand includes cash and short-term highly liquid investments with a short maturity of three months or less.

II) Financial liabilities

Basic financial liabilities, including trade and other payables, are initially recognised at transaction price. Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Financial liabilities held at amortised cost comprise all creditors except social security and other taxes and provisions.

Provisions

Provisions are recognised where the Society has a present legal or constructive obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Provisions are measured at the present value or the expenditures expected to be required to settle the obligation.

Notes to the financial statements

Fund accounting

Unrestricted funds are those funds available to the Society and Group for general purposes. They include funds designated by the Trustees for particular purposes where their use remains at the discretion of the Trustees. It is the policy of the Trustees to retain in unrestricted funds, amounts which in their judgement, can help to mitigate the short-term effects of income volatility; and retain as long-term investment funds to generate sufficient income to meet current and future operational activities of the Society.

Restricted funds are those funds available to the Society and Group restricted to a specific purpose or are subject to particular donor imposed conditions. Further information is available in the reserves section of the Trustees' report.

2 Income from grants and donations

| | Unrestricted funds £'000 | Restricted funds £'000 | 2023 Total funds £'000 | 2022 Total funds £'000 |
|--------------|--------------------------------|------------------------------|---------------------------------|---------------------------------|
| Grants | - | 217 | 217 | 249 |
| Donations | - | 208 | 208 | 31 |
| Total | - | 425 | 425 | 280 |

3 Income from investments and interest

| | Unrestricted £'000 | Restricted £'000 | 2023 Total £'000 | 2022 Total £'000 |
|-----------------------|-----------------------|---------------------|------------------------|------------------------|
| Listed investments | | | | |
| Investment Income | 131 | - | 131 | 151 |
| Bank deposit interest | 1 | - | 1 | - |
| Total | 132 | - | 132 | 151 |

4 Income from charitable activities

| | Unrestricted funds £'000 | Restricted funds £'000 | 2023 Total funds £'000 | 2022 Total funds £'000 |
|-----------------------------------|--------------------------------|------------------------------|---------------------------------|---------------------------------|
| Member subscriptions | 162 | - | 162 | 160 |
| BSI-CIPN | 105 | - | 105 | - |
| Corporates and partnership income | 105 | 15 | 120 | 136 |
| Congress | 643 | - | 643 | 512 |
| Meetings and events | 83 | - | 83 | 59 |
| Journals | 749 | - | 749 | 913 |
| Training | 28 | - | 28 | - |
| Total | 1,874 | 15 | 1,889 | 1,780 |

Notes to the financial statements

5 Total expenditure

| | Unrestricted funds £'000 | Designated funds £'000 | Restricted funds £'000 | 2023 Total £'000 |
|--------------------------------|--------------------------------|------------------------------|------------------------------|------------------------|
| <i>Raising funds</i> | | | | |
| Investment management fees | 35 | - | - | 35 |
| Fundraising | 12 | - | - | 12 |
| <i>Charitable Expenditure:</i> | | | | |
| Membership | 241 | - | - | 241 |
| BSI-CIPN | 80 | - | - | 80 |
| Partnership work | 147 | - | - | 147 |
| Congress | 720 | - | - | 720 |
| Other meetings and events | 289 | - | - | 289 |
| Journals | 370 | - | - | 370 |
| Training | 35 | 59 | - | 94 |
| Education and Careers | 64 | 136 | - | 200 |
| Diversity and inclusion | 2 | - | - | 2 |
| National Research support | - | - | 129 | 129 |
| Policy and Public Affairs | 21 | - | 158 | 179 |
| Public engagement | 73 | - | 38 | 111 |
| Communications | 221 | - | - | 221 |
| International Work | 23 | - | - | 23 |
| Total | 2,333 | 195 | 325 | 2,853 |

Allocation of support costs to charitable activities:

| | Direct costs £'000 | Support costs £'000 | 2023 Total £'000 |
|------------------------------|--------------------------|---------------------------|------------------------|
| <i>Raising funds</i> | | | |
| Investment management fees | 35 | - | 35 |
| Cost of raising funds | 12 | - | 12 |
| <i>Charitable activities</i> | | | |
| Membership | 185 | 56 | 241 |
| BSI-CIPN | 52 | 28 | 80 |
| Partnership work | 119 | 28 | 147 |
| Congress | 664 | 56 | 720 |
| Other meetings and events | 261 | 28 | 289 |
| Journals | 290 | 80 | 370 |
| Training | 66 | 28 | 94 |
| Education and Careers | 173 | 27 | 200 |
| Diversity and inclusion | 2 | - | 2 |
| National Research support | 129 | - | 129 |
| Policy and Public Affairs | 135 | 44 | 179 |
| Public engagement | 83 | 28 | 111 |
| Communications | 117 | 104 | 221 |
| International Work | 23 | - | 23 |
| Total | 2,346 | 507 | 2,853 |

Notes to the financial statements

5 Total expenditure (continued)

Support costs are as follows:

| | 2023 | 2022 |
|--|------------|------------|
| | £'000 | £'000 |
| Staff costs | 220 | 198 |
| Premises costs | 38 | 30 |
| Depreciation | 22 | 9 |
| IT and electronic communications costs | 90 | 67 |
| Other | 108 | 81 |
| Recruitment fees | 11 | 0 |
| Governance costs (note 6) | 18 | 13 |
| Total | 507 | 398 |

Support costs have been allocated based on time spent by departments supporting the various activities.

| | Unrestricted funds £'000 | Designated funds £'000 | Restricted funds £'000 | 2022 £'000 |
|--------------------------------|--------------------------------|------------------------------|------------------------------|---------------|
| <i>Raising funds</i> | | | | |
| Investment management fees | 41 | - | - | 41 |
| Fundraising | 30 | - | - | 30 |
| <i>Charitable Expenditure:</i> | | | | |
| Membership | 240 | - | - | 240 |
| Congress | 642 | - | - | 642 |
| Other meetings and events | 184 | - | - | 184 |
| Publications and journals | 370 | - | - | 370 |
| Policy and public affairs | 130 | - | 45 | 175 |
| National Research support | - | - | 149 | 149 |
| Partnership work | 133 | - | - | 133 |
| Education and careers | 68 | 125 | 5 | 198 |
| Diversity and inclusion | 4 | - | - | 4 |
| Public engagement | 116 | - | 2 | 118 |
| Communications | 228 | - | - | 228 |
| International work | 28 | - | - | 28 |
| Total | 2,214 | 125 | 201 | 2,540 |

Notes to the financial statements

6 Governance costs

| | 2023 | 2022 |
|--------------------------------|-----------|-----------|
| | £'000 | £'000 |
| Auditor's remuneration - audit | 14 | 12 |
| Auditor's remuneration - other | 4 | 1 |
| Total | 18 | 13 |

7 Net income before gains (losses) on investments

| | | |
|--------------------------------|-------|-------|
| This is stated after charging: | 2023 | 2022 |
| | £'000 | £'000 |
| Staff costs (note 9) | 1,229 | 1,182 |
| Depreciation | 30 | 9 |
| Auditor's remuneration - audit | 14 | 12 |
| Auditor's remuneration - other | 4 | 1 |

Notes to the financial statements

8 Staff costs

Staff costs during the year were as follows:

| | 2023 £'000 | 2022 £'000 |
|-----------------------|---------------|---------------|
| Wages and salaries | 1,054 | 1,009 |
| Social security costs | 122 | 118 |
| Pension costs | 53 | 55 |
| Total | 1,229 | 1,182 |

The average monthly number of employees during the year was as follows:

| | 2023 | 2022 |
|-------------------------------|-----------|-----------|
| Direct charitable activities | 15 | 16 |
| Administration of the charity | 3 | 3 |
| | 18 | 19 |

Number of employees whose annualised emoluments fall within following ranges for the year:

| | 2023 | 2022 |
|---------------------|------|------|
| £60,001 - £70,000 | 1 | 1 |
| £80,001 - £90,000 | 2 | 2 |
| £140,001 - £150,000 | 1 | 1 |

Pension contributions for these employees were £22,601 (2022 - £21,848).

The number of staff for whom retirement benefits are accruing under money purchase pension schemes amounted to 19 (2022 – 19).

The Society considers its key management personnel comprise the Trustees and the Senior Management Team (SMT). The Trustees provide their time free of charge. The total remuneration, employer's national insurance contributions, benefits and pensions paid to the SMT was £524,335 (2022 - £516,095).

The relevant staff costs have been included in the costs of charitable activities. The gender split in the society workforce is 67% female 33% male (2022: 74% female 26% male). All roles are evaluated and paid in accordance with external benchmarking irrespective of gender.

9 Trustees' remuneration

No trustees received any remuneration for his or her services during the year (2022 – none). During the year expenses totalling £6,933 (2022 - £4,783) were reimbursed to 14 trustees (2022 – 7). In addition £9,293 was paid for travel and accommodation costs on behalf of trustees (2022: £5,483).

In 2022 one trustee received a £250 BSI Congress 2021 Education and Public poster prize for best presentation and a Communicating Immunology grant of £1,000 for his project entitled 'Superbugs'.

Notes to the financial statements

10 Tangible assets of the Group and charity

| | Website £'000 | Computer equipment £'000 | Total £'000 |
|--------------------------|------------------|--------------------------------|----------------|
| Cost or valuation | | | |
| At 1 July 2022 | 38 | 30 | 68 |
| Additions | 18 | 3 | 21 |
| Disposals | - | - | - |
| At 30 June 2023 | 56 | 33 | 89 |
| Depreciation | | | |
| At 1 July 2022 | - | 20 | 20 |
| Charge for the year | 9 | 7 | 16 |
| Eliminated on disposal | - | - | - |
| At 30 June 2023 | 9 | 27 | 36 |
| Net book value | | | |
| At 30 June 2023 | 47 | 6 | 53 |
| At 1 July 2022 | 38 | 10 | 48 |

11 Intangible assets of the Group and charity

| | IT software £'000 | Total £'000 |
|--------------------------|----------------------|----------------|
| Cost or valuation | | |
| At 1 July 2022 | 93 | 93 |
| Additions | - | - |
| Disposals | - | - |
| At 30 June 2023 | 93 | 93 |
| Depreciation | | |
| At 1 July 2022 | - | - |
| Charge for the year | 14 | 14 |
| Eliminated on disposal | - | - |
| At 30 June 2023 | 14 | 14 |
| Net book value | | |
| At 30 June 2023 | 79 | 79 |
| At 1 July 2022 | 93 | 93 |

Construction of a new CRM system was completed during the year.

Notes to the financial statements

12 Investments

| | Group | | Charity | |
|-------------------------------------|--------------|--------------|--------------|--------------|
| | 2023 | 2022 | 2023 | 2022 |
| | £'000 | £'000 | £'000 | £'000 |
| Market value at 1 July 2022 | 4,029 | 4,196 | 4,029 | 4,196 |
| Disposals proceeds | (1,669) | (521) | (1,669) | (521) |
| Realised gains/(losses) | 14 | (57) | 14 | (57) |
| Additions at cost | 933 | 659 | 933 | 659 |
| Unrealised gains | (21) | (248) | (21) | (248) |
| Market value at 30 June 2023 | 3,286 | 4,029 | 3,286 | 4,029 |
| Cash held with investment managers | 13 | 230 | 13 | 230 |
| Investment in UKPIN | - | - | 7 | - |
| Total investments | 3,299 | 4,259 | 3,306 | 4,259 |

Total Group investments includes £100 investment in subsidiary.

| At 30 June 2023 the listed investments comprised the following: | Group | | Charity | |
|---|--------------|--------------|--------------|--------------|
| | 2023 | 2022 | 2023 | 2022 |
| | £'000 | £'000 | £'000 | £'000 |
| UK equities | 816 | 1,244 | 816 | 1,244 |
| Overseas equities | 1,779 | 2,270 | 1,779 | 2,270 |
| Investment instruments | 691 | 515 | 691 | 515 |
| Total | 3,286 | 4,029 | 3,286 | 4,029 |
| Historical cost of listed investments | 2,805 | 3,317 | 2,805 | 3,317 |

Investments representing more than 5% of the total market value of the portfolio of listed investments are as follows:

| | Cost 2023 £'000 | Market value 2023 £'000 | Portfolio % |
|---|-----------------------|----------------------------------|----------------|
| Aberdeen Standard Capital Offshore Fixed Interest Fund Institutional Income Z GBP | 240 | 209 | 6.35% |

Notes to the financial statements

12 Investments (continued)

Investment in subsidiary undertaking

The Society has two wholly owned trading subsidiaries. A summary of their trading results are shown below.

BSI Trading Limited is incorporated in England and Wales, registered number 01021739. Its registered office is 9 Appold Street London EC2A 2AP. The principal activity of the company is the management of corporate membership, sponsorship, exhibition and other trading activities for the Society.

The Society become sole member of United Kingdom Primary Immunodeficiency Network (UKPIN) on 20 December 2022 and accordingly on that date UKPIN became a subsidiary of the group. During the year UKPIN transferred £175k to the Society being most of its net assets on the acquisition date.

UKPIN is incorporated in England and Wales, registered number 09273983. Its registered office is 9 Appold Street, London EC2A 2AP. The principal activity of the company was the advancement of health among those with primary immunodeficiency disorders and advancing education in PID and related subjects. These activities have been transferred to the Society's Clinical Immunology Professional Network (BSI-CIPN).

A summary of the results of the subsidiaries is shown below:

| | 2023 | | | 2022 | | |
|---------------------------------------|------------------------------|----------------|----------------|------------------------------|----------------|----------------|
| | BSI Trading Limited £'000 | UKPIN £'000 | Total £'000 | BSI Trading Limited £'000 | UKPIN £'000 | Total £'000 |
| Turnover | 576 | - | 576 | 354 | - | 354 |
| Operating costs | - | - | - | - | - | - |
| Operating profit | 576 | - | 576 | 354 | - | 354 |
| Administration costs | (87) | (5) | (92) | (19) | - | (19) |
| Profit(loss) for the financial period | 489 | (5) | 484 | 335 | - | 335 |
| Distribution to parent charity | (489) | (175) | (664) | (335) | - | (335) |
| Retained in subsidiary | - | (180) | - | - | - | - |

The assets and liabilities of the subsidiaries were:

| | | | | | | |
|-------------|-------|---|-------|-------|---|-------|
| Assets | 600 | 2 | 602 | 388 | - | 388 |
| Liabilities | (600) | - | (600) | (388) | - | (388) |
| Net assets | - | 2 | 2 | - | - | - |

Notes to the financial statements

13 Debtors

| | Group | | Charity | |
|---------------------------------------|------------|------------|--------------|------------|
| | 2023 | 2022 | 2023 | 2022 |
| | £'000 | £'000 | £'000 | £'000 |
| Trade debtors | 389 | 358 | 425 | 341 |
| Prepayments and accrued income | 303 | 194 | 303 | 194 |
| Amount owed by subsidiary undertaking | - | - | 497 | 340 |
| Total | 692 | 552 | 1,225 | 875 |

14 Creditors

| | Group | | Charity | |
|---------------------------------------|------------|--------------|------------|--------------|
| | 2023 | 2022 | 2023 | 2022 |
| | £'000 | £'000 | £'000 | £'000 |
| Trade creditors | 74 | 355 | 74 | 345 |
| Other taxes and social security costs | 40 | 39 | 40 | 39 |
| VAT payable | 9 | 5 | 9 | 5 |
| Other creditors | 177 | 124 | 177 | 124 |
| Accruals and deferred income | 504 | 527 | 488 | 490 |
| Total | 804 | 1,050 | 788 | 1,003 |

Included within the above is deferred income as set out below:

| | Group | Charity |
|---|------------|------------|
| | 2023 | 2023 |
| | £'000 | £'000 |
| Deferred income brought forward at 1 July | 459 | 422 |
| Additional income deferred during the year | 437 | 422 |
| Brought forward funds released in the year | (459) | (422) |
| Deferred income carried forward at 30 June | 437 | 422 |

Deferred income comprises advance payments of journal royalties and memberships fees.

Notes to the financial statements

15 Restricted funds

| | At 1 July 2022 | Income | Expenditure | At 30 June 2023 |
|---|-------------------|------------|--------------|--------------------|
| Meeting funds | 34 | - | - | 34 |
| BSI-CIPN | - | 178 | - | 178 |
| Autoimmunity | 12 | - | (12) | - |
| UK-CIC | - | 63 | (63) | - |
| Vaccine taskforce | 1 | 25 | (26) | - |
| UK Covid Vaccines Research | 61 | 63 | (124) | - |
| Ageing and immunity | - | 68 | (40) | 28 |
| SIREN | 8 | 9 | (17) | - |
| Immunogenicity project | 27 | 15 | (42) | - |
| STRAVINSKY | - | 15 | (1) | 14 |
| Visiting Scholar and Jonathan Sherrard Awards | - | 4 | - | 4 |
| Total | 143 | 440 | (325) | 258 |

Meeting funds

Donations to the Society by individuals to promote certain immunological issues.

BSI-CIPN

Funds transferred from UKPIN upon the merger to be used to promote and support clinical immunology through the BSI-CIPN

Autoimmunity

A grant from the Lorna and Yuti Chernajovsky Biomedical Research Foundation for administrative support for the development and management of the autoimmune research initiative.

UK-CIC

A grant for the BSI support provided to the UK Coronavirus Immunology Consortium (UK-CIC) to understand the immunology of SARS-CoV-2 and COVID-19.

Vaccine taskforce

Funding from the European Federation of Immunological Societies (EFIS) for the EFIS Vaccine Taskforce work led by the BSI.

UK Covid Vaccines Research Hub

Central co-ordination hub for COVID-19 immunology research investments and outcomes funded by UKRI via the National Core Studies programme.

Notes to the financial statements

15 Restricted funds (Continued)

Ageing and immunity

The CARINA (Catalyst Reducing ImmuNe Ageing) Network is a new collaborative network for researchers working on the immune system throughout the life course. The BSI has a leading role in supporting the network through provision of project management, events support, communications expertise and patient and public involvement (PPI).

SIREN

Recruitment, facilitation and reporting of findings from Patient and Participant Involvement workshops for the SIREN project funded by the UK Health Security Agency.

Immunogenicity project

Immunogenicity measures in vaccine development and decision making programme funded by Merck Sharp & Dohme (UK) Limited.

STRAVINSKY

Funds to support a 2 year study aiming to establish if antibody testing can identify who remains at greatest risk of severe COVID-19 infection after vaccinations.

Visiting Schloar and Jonathan Sherrard Awards

Funds to support members for periods of training in academic or clinical centres to further their knowledge of primary immunodeficiencies.

| | At 1 July 2021 £'000 | Income £'000 | Expenditure £'000 | At 30 June 2022 £'000 |
|----------------------------|----------------------------|-----------------|----------------------|-----------------------------|
| Meeting funds | 34 | - | - | 34 |
| Autoimmunity | 10 | 15 | (13) | 12 |
| UK-CIC | (24) | 53 | (29) | - |
| Vaccine taskforce | - | 25 | (24) | 1 |
| BiteSized immunology | 5 | - | (5) | - |
| UK Covid Vaccines research | - | 157 | (96) | 61 |
| Ageing and immunity | - | 24 | (24) | - |
| SIREN | - | 10 | (2) | 8 |
| Immunogenicity project | - | 35 | (8) | 27 |
| Total | 25 | 319 | (201) | 143 |

16 Designated funds

| | At 1 July 2022 | Designated in year | Utilised / released | At 30 June 2023 |
|------------------------------|-------------------|-----------------------|------------------------|--------------------|
| Long term sustainability | 248 | - | (150) | 98 |
| Training | - | 150 | (59) | 91 |
| CRM project | 23 | - | (23) | - |
| Career development programme | 500 | - | (136) | 364 |
| Total | 771 | 150 | (368) | 553 |

Notes to the financial statements

16 Designated funds (Continued)

Long term sustainability

The long term sustainability fund provides resources for investing in the financial sustainability of the charity over the next five years.

Training

Funding for the creation and development of a new surplus generating training function within the BSI.

CRM project

The CRM project fund provides resources to develop and implement a new CRM system together with an upgrade to the BSI website

Career development programme

The Career development programme will fund a significant expansion in the careers support the BSI offers to our members. This includes two main streams: our career-enabling activities and our career-enhancing activities.

17 Analysis of net assets between funds

| | | | | 2023 |
|-----------------------|--------------------------------|------------------------------|------------------------------|----------------------|
| Group | Unrestricted funds £'000 | Designated funds £'000 | Restricted funds £'000 | Total funds £'000 |
| Tangible fixed assets | 53 | - | - | 53 |
| Intangible assets | 79 | - | - | 79 |
| Investments | 3,299 | - | - | 3,299 |
| Current assets | 458 | 553 | 258 | 1,269 |
| Current liabilities | (804) | - | - | (804) |
| Total Funds | 3,086 | 553 | 258 | 3,897 |

| | | | | 2023 |
|-----------------------|--------------------------------|------------------------------|------------------------------|----------------------|
| Charity | Unrestricted funds £'000 | Designated funds £'000 | Restricted funds £'000 | Total funds £'000 |
| Tangible fixed assets | 53 | - | - | 53 |
| Intangible assets | 79 | - | - | 79 |
| Investments | 3,306 | - | - | 3,306 |
| Current assets | 439 | 553 | 258 | 1,250 |
| Current liabilities | (788) | - | - | (788) |
| Total Funds | 3,090 | 553 | 258 | 3,901 |

Notes to the financial statements

17 Analysis of nets assets between funds (Continued)

The total unrealised gains (losses) as at 30 June 2023 constitutes movements on revaluation and are as follows:

| | 2023 £'000 | 2022 £'000 |
|--|---------------|---------------|
| Unrealised gains (losses) included above: | | |
| On investments | 962 | 983 |
| Total unrealised gains (losses) at 30 June | 962 | 983 |
| Reconciliation of movements in unrealised gains (losses) | | |
| Unrealised gains at 1 July | 983 | 522 |
| Less: in respect to disposals in the year | - | - |
| | 983 | 522 |
| Add: net gains (losses) arising on revaluation arising in the year | (21) | 461 |
| Total unrealised gains (losses) at 30 June | 962 | 983 |

| | | | | 2022 Total funds £'000 |
|-------------------------|--------------------------------|------------------------------|------------------------------|------------------------------|
| Group | Unrestricted funds £'000 | Designated funds £'000 | Restricted funds £'000 | |
| Tangible fixed assets | 49 | - | - | 49 |
| Intangible fixed assets | 93 | - | - | 93 |
| Investments | 4,259 | - | - | 4,259 |
| Current assets | 45 | 771 | 143 | 959 |
| Current liabilities | (1,050) | - | - | (1,050) |
| Total Funds | 3,396 | 771 | 143 | 4,310 |

| | | | | 2022 Total funds £'000 |
|-------------------------|--------------------------------|------------------------------|------------------------------|------------------------------|
| Charity | Unrestricted funds £'000 | Designated funds £'000 | Restricted funds £'000 | |
| Tangible fixed assets | 49 | - | - | 49 |
| Intangible fixed assets | 93 | - | - | 93 |
| Investments | 4,259 | - | - | 4,259 |
| Current assets | 25 | 771 | 116 | 912 |
| Current liabilities | (1,003) | - | - | (1,003) |
| Total Funds | 3,423 | 771 | 116 | 4,310 |

Notes to the financial statements

18 Share capital

The company is limited by guarantee and therefore has no share capital. Each member's liability is limited to £1.

19 Related party transactions

The Kennedy Trust for Rheumatology Research (charity No. 260059) provided £5,000 sponsorship for the BSI awards. Professor Tracy Hussell is a trustee of this charity.

Matthias Eberl received a £250 BSI Congress 2021 Education and Public poster prize and a Communicating Immunology grant of £1,000.

There were no other related party transactions that required disclosure in the current financial period (2022: none).

Notes to the financial statements

20 Comparative consolidated statement of financial activities

| | Unrestricted funds | | | 2022 |
|--|--------------------|---------------------|---------------------|--------------|
| | General £'000 | Designated £'000 | Restricted £'000 | £'000 |
| Income from: | | | | |
| Donations | 6 | - | 274 | 280 |
| Investments | 151 | - | - | 151 |
| Charitable activities | | | | |
| Membership | 160 | - | - | 160 |
| Partnership work | 91 | - | 45 | 136 |
| Congress | 512 | - | - | 512 |
| Meetings and events | 59 | - | - | 59 |
| Journals | 913 | - | - | 913 |
| Total income | 1,892 | - | 319 | 2,211 |
| Raising funds | | | | |
| Investment Management Fees | 41 | - | - | 41 |
| Cost of raising funds | 30 | - | - | 30 |
| Charitable activities | | | | |
| Membership | 240 | - | - | 240 |
| Congress | 642 | - | - | 642 |
| Meetings and events | 184 | - | - | 184 |
| Publications and journals | 370 | - | - | 370 |
| Policy and Public Affairs | 130 | - | 45 | 175 |
| National Research support | - | - | 149 | 149 |
| Partnership work | 133 | - | - | 133 |
| Education and Careers | 68 | 125 | 5 | 198 |
| Diversity and inclusion | 4 | - | - | 4 |
| Public engagement | 116 | - | 2 | 118 |
| Communications | 228 | - | - | 228 |
| International work | 28 | - | - | 28 |
| Total expenditure | 2,214 | 125 | 201 | 2,540 |
| Net income (expenditure) before gains (losses) on investments and transfers | (322) | (125) | 118 | (329) |
| Net gains/(losses) on investments | (305) | - | - | (305) |
| Transfers between funds | 90 | (90) | - | - |
| Net income | (537) | (215) | 118 | (634) |
| Reconciliation of funds: | | | | |
| Funds brought forward | 3,933 | 986 | 25 | 4,944 |
| Funds carried forward | 3,396 | 771 | 143 | 4,310 |

Notes to the financial statements

21 Charity statement of financial activities

| | Unrestricted funds | | | | |
|--|---------------------------|------------------------------|------------------------------|------------------------|------------------------|
| | General funds £'000 | Designated funds £'000 | Restricted funds £'000 | Total 2023 £'000 | Total 2022 £'000 |
| Income from: | | | | | |
| Grants and donations | - | - | 425 | 425 | 290 |
| Investments | 132 | - | - | 132 | 151 |
| Charitable activities | | | | | |
| Membership | 162 | - | - | 162 | 160 |
| BSI-CIPN | 3 | - | - | 3 | - |
| Partnership work | 38 | - | - | 38 | 40 |
| Congress | 300 | - | - | 300 | 293 |
| Meetings and events | 49 | - | - | 49 | 11 |
| Journals | 749 | - | - | 749 | 913 |
| Training | 12 | - | - | 12 | - |
| Gift Aid and recharge from BSI | 575 | - | - | 575 | 353 |
| Trading Limited | | | | | |
| Total income | 2,020 | - | 425 | 2,445 | 2,211 |
| Expenditure on: | | | | | |
| Raising funds | | | | | |
| Investment management fees | 35 | - | - | 35 | 41 |
| Cost of raising funds | 12 | - | - | 12 | 30 |
| Charitable activities | | | | | |
| Membership | 242 | - | - | 242 | 240 |
| BSI-CIPN | 80 | - | - | 80 | - |
| Partnership work | 147 | - | - | 147 | 133 |
| Congress | 720 | - | - | 720 | 642 |
| Meetings and events | 289 | - | - | 289 | 184 |
| Journals | 370 | - | - | 370 | 370 |
| Training | 35 | 59 | - | 94 | - |
| Education and Careers | 64 | 136 | - | 200 | 198 |
| Diversity and inclusion | 2 | - | - | 2 | 4 |
| National Research support | - | - | 129 | 129 | 149 |
| Policy and Public Affairs | 56 | - | 115 | 171 | 175 |
| Public engagement | 73 | - | 38 | 111 | 118 |
| Communications | 221 | - | - | 221 | 228 |
| International work | 23 | - | - | 23 | 28 |
| Total expenditure | 2,369 | 195 | 283 | 2,847 | 2,537 |
| Net income (expenditure) before gains (losses) on investments and transfers | (349) | (195) | 142 | (402) | (326) |
| Net gains/(losses) on investments | (7) | - | - | (7) | (305) |
| Transfers between funds | 23 | (23) | - | - | - |
| Net income/(deficit) | (333) | (218) | 142 | (409) | (632) |
| Reconciliation of funds: | | | | | |
| Funds brought forward | 3,423 | 771 | 116 | 4,310 | 4,944 |
| Funds carried forward | 3,089 | 553 | 258 | 3,900 | 4,312 |

Board of Trustees

| Position | Trustee | Date of appointment / resignation |
|----------------------|--------------------------|-----------------------------------|
| Previous | | |
| Past President | Professor Arne Akbar | Resigned December 2022 |
| Past Chair of Forum | Professor Ann Ager | Resigned December 2022 |
| Early Career Trustee | Dr Calum Bain | Resigned July 2022 |
| Trustee | Professor Matthias Eberl | Resigned June 2023 |
| Co-opted Trustee | Dr Paul Harding | Resigned June 2023 |
| Trustee | Professor Allan Mowat | Resigned June 2023 |

| | | |
|----------------------|--------------------------------|-------------------------|
| Current | | |
| President | Professor Tracy Hussell | Appointed December 2022 |
| Treasurer | Dr Fiona Culley | Re-appointed July 2022 |
| Chair of Forum | Professor James Brewer | Appointed December 2022 |
| Clinical Secretary | Professor Colin Dayan | Appointed October 2019 |
| Early Career Trustee | Dr Emma Chambers | Appointed December 2018 |
| Co-opted Trustee | Robert Davies | Re-appointed July 2023 |
| Trustee | Professor Deborah Dunn-Walters | Re-appointed July 2023 |
| Co-opted Trustee | Dr Edith Hessel | Appointed January 2017 |
| Trustee | Professor Teresa Lambe | Appointed December 2022 |
| Co-opted Trustee | James Lowe | Appointed July 2019 |
| Co-opted Trustee | David Pemberton | Appointed July 2023 |
| Early Career Trustee | Dr Matthew Siggins | Appointed July 2022 |
| Co-opted Trustee | Dr Sinisa Savic | Appointed July 2022 |
| Trustee | Dr Divya Shah | Re-appointed July 2023 |
| Trustee | Dr Jessica Strid | Appointed July 2023 |

Board composition



Gender (%)

| | |
|--------|----|
| Female | 53 |
| Male | 47 |



Length of tenure (%)

| | |
|-----------|----|
| < 1 year | 40 |
| 1-3 years | 27 |
| > 4 years | 33 |

Leadership

Board and Committee meetings and attendance

All Trustees are expected to attend each Board meeting and each Committee meeting for which they are members, unless there are exceptional circumstances preventing them from participating. The table below shows the attendance at Board and other BSI committees.

| Trustees | BSI-CIPN | | Congress Committee | Finance Sub Committee | Membership | |
|--------------------------------|----------|-------------------|-----------------------|--------------------------|-------------------------|--------------------------|
| | Board | Steering Group | | | Representative Forum | Nominations Committee |
| Professor Tracy Hussell | 4/4 | - | 3/3 | - | 3/3 | 1/1 |
| Dr Fiona Culley | 4/4 | - | 1/4 | 5/5 | - | - |
| Professor James Brewer | 1/2 | - | - | - | 3/3 | 1/1 |
| Professor Colin Dayan | 4/4 | - | 1/4 | - | 1/4 | - |
| Dr Emma Chambers | 4/4 | - | - | - | - | - |
| Robert Davies | 4/4 | - | - | - | - | 1/1 |
| Professor Deborah Dunn-Walters | 3/4 | - | - | - | - | - |
| Dr Edith Hessel | 3/4 | - | 1/1 | - | - | 1/1 |
| Professor Teresa Lambe | 2/2 | - | - | - | - | 1/1 |
| James Lowe | 3/4 | - | - | 5/5 | - | - |
| David Pemberton | 0/0 | - | - | 0/0 | - | - |
| Dr Matthew Siggins | 4/4 | - | - | - | - | - |
| Dr Sinisa Savic | 2/4 | 2/2 | - | - | - | - |
| Dr Divya Shah | 2/2 | - | - | - | - | - |
| Dr Jessica Strid | 0/0 | - | - | - | - | - |

Senior Management Team

| Name | Position |
|-----------------|------------------------------|
| Dr Doug Brown | Chief Executive |
| Otto Balsiger | Finance Director |
| Dr Jennie Evans | Director of External Affairs |
| Jane Sessenwein | Head of Events & Conferences |
| Lucy McIver | Head of Publishing |

Principal professional advisers

| Name | Advisor |
|---------------------|--|
| Bankers | Bank of Scotland 14/16 Cockspur Street London EC2V 6DL |
| External auditors | Moore Kingston Smith LLP 9 Appold Street London EC2A 2AP |
| Investment advisers | Abrdn (formerly Aberdeen Standard Chartered) 14th Floor 30 St Mary Axe London EC3A 8BF |
| Solicitors | Russell Cooke LLP 2 Putney Hill London SW15 6AB |

Committees

Nominations Committee

| Members | |
|-------------------------|----------------------|
| Professor Tracy Hussell | Chair, BSI President |
| Robert Davies | BSI Co-opted Trustee |
| Professor James Brewer | Trustee |
| Professor Teresa Lambe | Trustee |
| Dr Doug Brown | BSI CEO (observer) |

Finance Sub Committee

| Members | |
|-----------------|----------------------|
| Dr Fiona Culley | BSI Treasurer |
| James Lowe | Co-opted Trustee |
| David Pemberton | Co-opted Trustee |
| Dr Doug Brown | BSI Chief Executive |
| Otto Balsiger | BSI Finance Director |

Forum

| Members | |
|--------------------------|--|
| Professor James Brewer | Chair |
| Professor Tracy Hussell | BSI President |
| Dr Colin Dayan | Clinical Secretary |
| Dr Donald Palmer | Education & Careers Secretary |
| Professor Matthias Eberl | Public Engagement Secretary |
| Dr Doug Brown | BSI Chief Executive |
| Dr Jennie Evans | BSI Director of External Affairs |
| Dr Patrick Cao | Regional Representative - Scotland |
| Dr Julia Makinde | Regional Representative - England |
| Dr Karim Dib | Regional Representative - Northern Ireland |
| Dr Simone Cuff | Regional Representative - Wales |
| Dr Louise Topping | Early Career Representative |
| Dr George Robinson | Early Career Representative |
| Dr George Robinson | Early Career Representative |
| Dr Edoardo Prediletto | Early Career Representative |
| Dr Lauren Campbell | PhD Representative |
| Dr Jhanna Kryukova | PhD Representative |
| Dr Chloe Pyle | Industry Representative |
| Dr Gareth-Rhys Jones | Clinical Representative |
| Dr Tomaz Garcez | Clinical Representative |
| Dr Rebecca McLean | Veterinary Representative |

Committees

Congress Committee

| Name | Position |
|-------------------------|----------------------------------|
| Professor Mark Coles | BSI Congress Secretary |
| Professor Tracy Hussell | BSI President |
| Dr Fiona Culley | BSI Treasurer |
| Dr Colin Dayan | BSI Clinical Secretary |
| Dr Edith Hessell | Member |
| Dr Daniel O'Connor | Early Career Representative |
| Dr Graham Cook | Member |
| Dr Helen McGettrick | Member |
| Dr Henry McSorley | Member |
| Dr James Harker | Member |
| Dr James Thaventhiran | Clinical member |
| Dr Laura Rivino | Member |
| Dr Margarita Dominguez | Member |
| Dr Sandra Sacre | Member |
| Jane Sessenwein | BSI Head of Events & Conferences |

BSI-CIPN Steering Group

| Name | Position |
|------------------------|---|
| Dr Sinisa Savic | Chair |
| Dr Suzy Elcombe | Deputy Chair |
| Dr Catherine Stroud | Membership Lead |
| Sarah Denman | Pharmacy Representative |
| Dr Lisa Devlin | Industry Liaison |
| Jull Edmonds | Nursing Representative |
| Dr Kimberly Gilmour | Clinical/Biomedical Scientist Representative |
| Professor Alex Ritcher | Guidelines Lead |
| Dr Ravishnkar Sargur | Member |
| Dr Patrick Yong | Training & Education Lead |
| Dr Manisha Ahuja | Postgraduate Doctor in Training Representative |
| Position vacant | Patitent Group Liaison |
| Dr James Thaventhiran | Conference Lead (Co-opted member) |
| Dr Austen Worth | Paediatric Representative and PID Registry Representative (Ex-officio member) |
| Dr Claire Bethune | CRG Representative (Ex-officio member) |
| Dr Sarah Goddard | QPIDS Representative (Ex-officio member) |
| Dr Doug Brown | BSI Chief Executive |

Journals

Clinical and Experimental Immunology - Editorial Team

| Name | Position |
|------------------------------|--|
| Professor Leonie Taams | Editor-in-Chief |
| Professor Angelo Manfredi | Section Editor - autoimmunity |
| Professor Tanja de Gruiji | Section Editor - cancer immunity |
| Professor Ciriaco Piccirillo | Section Editor - immune-mediated inflammatory diseases |
| Dr Cindy Ma | Section Editor - immunodeficiency |
| Dr daniel Douek | Section Editor - infectious diseases and vaccines |
| Professor Xiao-Ning Xu | Section Editor - infectious diseases and vaccines |
| Professor Sandra Amor | Section Editor - neuroimmunology |

Immunotherapy Advances - Editorial Team

| Name | Position |
|------------------------------------|--------------------------------|
| Professor Tim Elliot | Editor-in-Chief |
| Professor Stefan Barth | Regional Editor: Africa |
| Associate Professor Marianne Boes | Regional Editor: Europe |
| Professor Adrianna Bonomo | Regional Editor: South America |
| Professor Tao Dong | Regional Editor: Asia |
| Dr Stephanie K Dougan | Regional Editor: North America |
| Associate Professor Menno van Zelm | Regional Editor: Australasia |

Discovery Immunology - Editorial Team

| Name | Position |
|---------------------------------|-----------------|
| Professor Simon Milling | Editor-in-Chief |
| Dr Philip Ahern | Senior Editor |
| Dr Awen Gallimore | Senior Editor |
| Dr Florent Ginhoux | Senior Editor |
| Dr Emily Gwyer Findlay | Senior Editor |
| Dr Lai Guan Ng | Senior Editor |
| Professor Francisco J. Quintana | Senior Editor |
| Dr Meera Ramanujam | Senior Editor |

Regional and Affinity groups

Affinity Groups

| Group | Position | Member |
|---|---------------------|------------------------------|
| Autoimmunity Affinity Group | Chair | Professor Lucy Walker |
| | Secretary | Dr Kathryn Steel |
| | Treasurer | Dr James Pearson |
| Comparative Veterinary Immunology Group | Chair | Wilhelm Gerner |
| | Secretary | Dr Lindert Benedictus |
| | Treasurer | Dr Kate Sutton |
| Immunometabolism Affinity Group | Co-Chair | Dr Laura Pallett |
| | Co-Chair | Dr Linda Sinclair |
| | Secretary | Dr Sarah Dimeloe |
| | Treasurer | Dr Anna Schurich |
| Immunosenescence Affinity Group | Chair | Dr Sian Henson |
| | Secretary | Dr Natalie Riddell |
| | Treasurer | Dr Catarina Henriques |
| Infection and Immunity Group | | |
| Inflammation Affinity Group | Chair | Professor Peter Barlow |
| | Treasurer | Dr Joanne Konkell |
| | Communications | Dr Jack Rivers-Auty |
| Leukocyte Migration Group | Chair | Dr Myriam Chimen |
| | Secretary/Treasurer | Dr Graeme O'Boyle |
| Mathematical Modelling Group | Chair | Dr Grant Lythe |
| | Secretary | Professor Mark Coles |
| | Treasurer | Dr Hashem Koohy |
| Neuroimmunology Group | Chair | Dr Yvonne Dombrowski |
| | Secretary | Dr Sarosh Irani |
| Teaching Affinity Group | Co-chair | Professor John Currow |
| | Co-chair | Dr Nigel Francis |
| | Secretary | Dr Owen Kavanagh |
| | Treasurer | Dr Becky Aicheler |
| Tumour Immunology Affinity Group | Chair | Professor Benjamin Willcox |
| | Secretary | Dr Seth B. Coffelt |
| | Treasurer | Professor Awen Gallimore |
| Vaccine Affinity Group | Chair | Dr Bernardo Villarreal-Ramos |
| | Secretary | Dr Julia Tree |
| | Treasurer | Dr Dirk Werling |

Regional and Affinity groups

Regional Groups

| Group | Position | Member |
|-------------------------------------|---------------------|-------------------------|
| Aberdeen Immunology Group | Chair | Dr Isabel Crane |
| | Treasurer | Dr Janine Coombes |
| Bristol Immunology Group | Chair | Dr Gareth Jones |
| | Secretary | Dr Dronwen Burton |
| | Treasurer | Dr Lindsay Nicholson |
| Cambridge Immunology Group | Chair | Dr Brian Ferguson |
| | Secretary/Treasurer | Dr Louise Boyle |
| East Anglia Immunology Group | Secretary | Dr Anastasia Sobolewski |
| | Treasurer | Dr Cristina Fanutti |
| Edinburgh Immunology Group | Co-Chair | Dr Rebecca Gentek |
| | Co-Chair | Dr Laura McCulloch |
| | Secretary | Dr Matthew Burgess |
| | Secretary | Dr Tovah Shaw |
| | Treasurer | Dr Sean Wattagedera |
| Greater Manchester Immunology Group | Chair | Dr Doug Dyer |
| | Secretary | Dr Andrew Greenhaigh |
| Immunology North East | Chair | Dr Kevin Marchbank |
| | Secretary | Dr Antony Antoniou |
| | Treasurer | Dr Andy Knight |
| London Immunology Group | Chair | Dr Laura Pallett |
| | Secretary | Dr Franze Progatzy |
| | Treasurer | Dr George Finney |
| Midlands Immunology Group | Chair | Dr Rebecca Drummond |
| | Treasurer | Dr Martin Davey |
| Oxford Immunology Group | Chair | Dr Roel De Maeyer |
| | Secretary | Dr Elena Mitsi |
| South Wales Immunology Group | Chair | Dr You Zhou |
| | Secretary | Dr Rebecca Aicheler |
| | Treasurer | Dr Ceri Fielding |

Regional and Affinity groups

Regional Groups

| Group | Position | Member |
|-----------------------------------|-----------|---------------------------|
| Tayside Immunology Group | Chair | Professor Simon Arthur |
| | Secretary | Dr Mahima Swamy |
| | Treasurer | Dr Shalini Pathak |
| Ulster Immunology Group | President | Dr Yvonne Dombrowski |
| | Secretary | Dr Karim Dib |
| | Treasurer | Dr Rebecca Coll |
| Wessex Immunology Group | Co-Chair | Professor Jessica Teeling |
| | Co-Chair | Dr Sarah Buchan |
| | Secretary | Dr Alison Hill |
| | Treasurer | Dr Diogo Silva |
| West of Scotland Immunology Group | Chair | Dr Megan MacLeod |
| | Secretary | Dr Ed Roberts |
| | Treasurer | Dr Hannah Scales |
| Yorkshire Immunology Group | Chair | Dr Gina Doody |
| | Secretary | Dr Erica Wilson |